




# Focus on Transmembrane Protein Drug Targets



400+ Transmembrane  
Proteins Available  
11000+ Developed Proteins  
6000+ Proteins in Stock

Overexpression  
Stable Cell Line  
Targeting Multipass  
Transmembrane  
Protein

Risk-Free Protein  
Expression Service  
Five Expression Systems  
& Three Transmembrane  
Protein Technology  
Platforms

Therapeutic  
Antibody Discovery  
Targeting Multipass  
Transmembrane  
Protein

Quality  
Antibodies Specific  
for Druggable  
Targets

• Virus-like  
particles (VLPs)  
• Detergent Micelle  
• Nanodisc

400+

15 times

High  
biological  
activity

ELISA  
SPR/BLI  
FACS

Strategy for  
expressing multipass  
transmembrane proteins

Successfully developed  
full-length membrane  
proteins


Multiple  
transmembrane times

Complete natural  
conformation


Multi-platform  
verification

|        |          |       |          |         |           |        |         |
|--------|----------|-------|----------|---------|-----------|--------|---------|
| GUCY2C | ROR1     | ENPP3 | CD44     | TACSTD2 | MSLN      | EPHA3  | PD-L1   |
| DLL3   | ULBP1    | ACE2  | CD276    | CD46    | CD33      | SIRPA  | CD48    |
| BSG    | TNFSF13B | CLDN3 | GHR      | ICOSLG  | CD47      | PD-1   | TNFR2   |
| TTR    | TNFRSF14 | CLDN4 | MET      | MIF     | CD40LG    | BTLA   | RBP4    |
| SECTM1 | TNFSF14  | CLDN6 | C5AR1    | CTLA4   | CD7       | NRP1   | TNFSF18 |
| TIGIT  | CD226    | CLDN9 | CLDN18.2 | CDH17   | NT5E      | LTA    | MUC16   |
| NRG1   | TNFR1    | HER2  | CXCR4    | TNFRSF8 | TNFSF8    | LIFR   | Dsg3    |
| LIF    | GPC3     | DLL3  | GPRC5D   | SEMA4D  | TNFRSF18  | L1CAM  | Gfral   |
| PLXNB1 | ERBB3    | MERTK | CD20     | GCGR    | TNFRSF11B | IGFL1  | NECTIN4 |
| PVR    | CSF2RB   | CD96  | SSTR2    | LY6G6D  | TNFRSF13C | ZNRF3  | Prlr    |
| CD40   | TNFSF9   | CD22  | CCR4     | PROM1   | RSPO1     | MAGEA4 | IGFLR1  |
| TFPI   | ALPI     | MAPT  | CCR8     | CNR1    | KLRK1     | CD93   | GLP1R   |

### ● High Purity Determined by SDS-PAGE.




The purity of HTR1B (CSB-CF010882HUB2) (7 times) is greater than 90% as determined by SDS-PAGE with 5% enrichment gel and 15% separation gel.




The purity of CLCN3 (CSB-CF005482HU(A4)) (15 times) is greater than 85% as determined by SDS-PAGE with 5% enrichment gel and 15% separation gel.

### ● High Specificity Validated by Western Blot (WB).




CLDN18.2 (CSB-MP005498HU(A5)) (4 times) is detected by Mouse anti-6\*His monoclonal antibody. The three bands respectively correspond to monomer, Homodimer, Homotrimer.




CD20 (CSB-MP015007HU) (4 times) is detected by Mouse anti-6\*His monoclonal antibody.

### ● Good Bioactivity Validated by Functional ELISA.




Immobilized ABCD1 (CSB-CF001068HU) (5 times) at 5 µg/ml can bind human PEX19, the EC50 of human PEX19 is 22.96-33.00 µg/ml.




Immobilized ACKR1 (CSB-CF624105HU) (7 times) at 1 µg/ml can bind human CCL2, the EC50 of human CCL2 protein is 48.64-60.24 µg/ml.

### ● Correct Structure Validated by TEM.



The VLP-like structures of CLDN18.2 (CSB-MP005498HU(A5)) (4 times) has been confirmed by TEM.



The VLP-like structures of CD20 (CSB-MP015007HU) (4 times) has been confirmed by TEM.



Everon life Science  
Khasra No.384/2, 2nd Floor, Village & Post- Ghitorni, MG Road,  
New Delhi-110030 Tel# 011-47053459, 9810306768, 8527119191  
Email: info@everonlife.com Web: www.everonlife.com



CUSABIO TECHNOLOGY LLC  
Postal Address: 7505 Fannin St., Ste 610, Room 7 {CUSABIO  
Innovation Center}, Houston, 1X77054, USA Tel: 301-363-4651  
Email: support@cusabio.com Web: www.cusabio.com